LMI Awarded DHA's OMNIBUS IV IDIQ Contract in All Four Market Segments

Tysons, Va. – LMI has been awarded the Defense Health Agency (DHA) OMNIBUS IV indefinite delivery, indefinite quantity (IDIQ) $10 billion contract in all four market segments: (1) Research and Development; (2) Research and Development Support Services; (3) Regulatory Processes; and (4) Translational Science Support and Services.

“We are excited to take LMI’s extensive experience in medical and biotechnological portfolios and assist the DHA in meeting their goals and objectives,” stated Karen LeDoux, director of LMI’s military health and Veterans Affairs submarket. “LMI has an incredible team of regulatory managers, clinical advisors, logisticians, scientists, and bioengineers.”

LMI provides advanced medical technology and scientific expertise support throughout the medical technology lifecycle—pre-discovery and target identification; in-process formulation; clinical, non-clinical, regulatory, and quality application; licensure, marketing, and post-marketing; and post-deployment system sustainment. LMI understands the unique technological challenges of every step (before, during, and after development), as well as how to characterize the impact and overcome each challenge. LMI approaches the development stages from a systems engineering perspective, ensuring decisions at the operational and organization levels do not have unintended consequences elsewhere in the system.

“We are excited to take LMI’s extensive experience in medical and biotechnological portfolios and assist the DHA in meeting their goals and objectives.” 

— Karen LeDoux, director of LMI’s military health and Veterans Affairs submarket

Doug Wagoner, president and CEO, stated, “I am proud of the value-added services and technical thought leadership, innovation, and objectivity LMI provides to the Defense Health Agency. Through assisting the DHA in addressing the complexities of medical research and development and translation science, we help improve the government’s understanding of infectious disease, genomics, emerging technology, and many other scientific fields.”

LMI’s thought leadership facilitated the transition and development of novel technologies for multiple programs of record, providing the government with unmatched medical countermeasures against chemical, biological, radiological, and nuclear and other threats; LMI’s most recent collaboration on a monoclonal antibody drug product is providing our nation another tool in their toolbox to combat COVID-19.

“Through assisting the DHA in addressing the complexities of medical research and development and translation science, we help improve the government’s understanding of infectious disease, genomics, emerging technology, and many other scientific fields.” 

— Doug Wagoner, president and CEO